{
    "clinical_study": {
        "@rank": "154542", 
        "acronym": "AXA", 
        "arm_group": [
            {
                "arm_group_label": "Enoxa", 
                "arm_group_type": "Active Comparator", 
                "description": "ENOXA\u00ae Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours"
            }, 
            {
                "arm_group_label": "Lovenox", 
                "arm_group_type": "Active Comparator", 
                "description": "LOVENOX\u00ae Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a clinical trial monocentric, open, randomized ENOXA \u00ae versus LOVENOX \u00ae,\n      conducted on two parallel groups of patients admitted in emergency for acute coronary\n      syndrome."
        }, 
        "brief_title": "Comparison of Anti-Xa Activity of ENOXA \u00ae Versus LOVENOX \u00ae in Acute Coronary Syndrome", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Factor X"
        ], 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "The patients included in this study with an acute coronary Syndrome be admitted to the\n      emergency room and receive treatment with enoxaparin. Low molecular weight heparin (LMWH)\n      treatment in this indication is usually spread over a week. The experience of the study\n      intends to focus only on the first injection administered in selected patients.\n\n      Two assays are carried out, including an assessment of the anti-Xa activity initially before\n      injection of enoxaparin, and 4 hours after administration of the first syringe.\n\n      Clinical monitoring is intrahospital from the date of hospitalization of patients included\n      until emergency exit (transfer to another service, or return home)\n\n      Tolerance assessment (clinical and biological) is performed during follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female over the age of 20 years\n\n          -  acute coronary syndrome\n\n          -  Admission to the emergency department\n\n        Exclusion Criteria:\n\n          -  Patient participating in another study\n\n          -  Pregnant or lactating or of childbearing potential not using medically accepted\n             method of contraception\n\n          -  Taking an anticoagulant in the last three months\n\n          -  Patient with known haemostatic disorder\n\n          -  Contraindication absolute and / or relative to the use of enoxaparin\n\n          -  Nobody wishing to participate in this study or not having the ability to understand\n             its objectives"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687491", 
            "org_study_id": "AXA_2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enoxa", 
                "intervention_name": "ENOXA\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "ENOXA\u00ae"
            }, 
            {
                "arm_group_label": "Lovenox", 
                "intervention_name": "LOVENOX\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "LOVENOX\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Enoxaparin", 
            "Acute Coronary Syndrome", 
            "Factor X"
        ], 
        "lastchanged_date": "September 18, 2012", 
        "location": {
            "contact": {
                "email": "semir.nouira@rns.tn", 
                "last_name": "Semir Nouira, PHD", 
                "phone": "+216 73 425 265"
            }, 
            "contact_backup": {
                "email": "mohsen.hassine@rns.tn", 
                "last_name": "Mohsen Hassine", 
                "phone": "+216 98 277 139"
            }, 
            "facility": {
                "address": {
                    "city": "Monastir", 
                    "country": "Tunisia", 
                    "zip": "5000"
                }, 
                "name": "Departement of Emergency"
            }, 
            "investigator": {
                "last_name": "Semir Nouira, PHD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Tunisia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA \u00ae Versus LOVENOX \u00ae", 
        "overall_contact": {
            "email": "semir.nouira@rns.tn", 
            "last_name": "S\u00e9mir Nouira, PHD", 
            "phone": "+216 73 425 265"
        }, 
        "overall_contact_backup": {
            "email": "mohsen.hassine@rns.tn", 
            "last_name": "Mohsen Hassine, PHD", 
            "phone": "+216 98 277 139"
        }, 
        "overall_official": [
            {
                "affiliation": "Fattouma Bourguiba Hospital, Monastir", 
                "last_name": "Semir Nouira, PHD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Fattouma Bourguiba, Monastir", 
                "last_name": "Mohsen Hassine", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Tunisia: Office of Pharmacies and Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "assay of anti-Xa activity 4 hours after the first injection \u00e9noxparine", 
            "measure": "anti-Xa activity", 
            "safety_issue": "No", 
            "time_frame": "4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tolerance is assessed by the occurrence of adverse events and / or serious adverse events", 
            "measure": "adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 7 days"
        }, 
        "source": "Les Laboratoires des M\u00e9dicaments St\u00e9riles", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "emergency department of the hospital  Fattouma Bourguiba Monastir", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Division of Hematology of the hospital  Fattouma Bourguiba Monastir", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Les Laboratoires des M\u00e9dicaments St\u00e9riles", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}